UNSPSC 51362202: Carbocloral

This classification denotes a sedative and hypnotic with the molecular formula C5H8Cl3NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K0KA807799, chemically known as ethyl 2,2,2-trichloro-1-hydroxyethylcarbamate but generally known as carbocloral, which bears US NIH Compound Identifier 10944. European Medicines Agency schedules Carbocloral in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06611MIG.

UNSPSC 51362202 Carbocloral is a Commodity code that encompasses pharmaceutical products and drug-related supplies procured by state and local health agencies, though recent solicitations tagged under this code show significant scope variance. State and local governments buying under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida recently solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB posted June 30, 2026, with a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities for implementing a direct-to-manufacturer prescription program, signaling state interest in alternative pharmacy procurement models beyond traditional wholesaler relationships. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products, requiring vendors to supply through three authorized wholesalers with proposals due March 26, 2026.

Recent activity spans Florida, Texas, and Minnesota, with the MMCAP cooperative extending participation to Oregon and other member states. The issuing bodies mix county health operations (Seminole County), state-level health agencies (Texas HHS), and multistate purchasing cooperatives (MMCAP), each targeting different supply-chain models—direct purchase, direct-to-manufacturer programs, and wholesaler-mediated distribution. The Minnesota RFP emphasizes price competitiveness weighted at 75 percent of evaluation, cGMP and Drug Supply Chain Security Act compliance, and maintenance of relationships with authorized wholesalers; vendors must carry commercial general liability insurance of $5 million per occurrence and accept a 3 percent administrative fee on all contract purchases. The code shows activity concentrated in health-sector procurement, though the diversity of solicitation types—IFB, RFI, and RFP—and the variance between naloxone procurement, direct-pharmacy initiatives, and multi-source generic drug supply suggests the tagging reflects broader pharmaceutical and health-supply categories rather than a single product line.